Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy

Autores
Bellini, Maria Jose; Labombarda, Maria Florencia
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Although little attention has been paid to cognitive and emotional dysfunctions observed in patients after spinal cord injury, several reports have described impairments in cognitive abilities. Our group also has contributed significantly to the study of cognitive impairments in a rat model of spinal cord injury. These findings are very significant because they demonstrate that cognitive and mood deficits are not induced by lifestyle changes, drugs of abuse, and combined medication. They are related to changes in brain structures involved in cognition and emotion, such as the hippocampus. Chronic spinal cord injury decreases neurogenesis, enhances glial reactivity leading to hippocampal neuroinflammation, and triggers cognitive deficits. These brain distal abnormalities are recently called tertiary damage. Given that there is no treatment for Tertiary Damage, insulin growth factor 1 gene therapy emerges as a good candidate. Insulin growth factor 1 gene therapy recovers neurogenesis and induces the polarization from pro-inflammatory towards anti-inflammatory microglial phenotypes, which represents a potential strategy to treat the neuroinflammation that supports tertiary damage. Insulin growth factor 1 gene therapy can be extended to other central nervous system pathologies such as traumatic brain injury where the neuroinflammatory component is crucial. Insulin growth factor 1 gene therapy could emerge as a new therapeutic strategy for treating traumatic brain injury and spinal cord injury.
Fil: Bellini, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner". Universidad Nacional de la Plata. Facultad de Ciencias Médicas. Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner"; Argentina
Fil: Labombarda, Maria Florencia. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Materia
COGNITIVE IMPAIRMENTS
GENE THERAPY
HIPPOCAMPUS
INSULIN GROWTH FACTOR 1
MICROGLIAL CELLS
NEURODEGENERATION
NEUROGENESIS
NEUROINFLAMMATION
SPINAL CORD INJURY
TRAUMATIC BRAIN INJURY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/227270
Acceder
id CONICETDig_4a5fa8a3338de3afe774e18ee6451951
oai_identifier_str oai:ri.conicet.gov.ar:11336/227270
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapyBellini, Maria JoseLabombarda, Maria FlorenciaCOGNITIVE IMPAIRMENTSGENE THERAPYHIPPOCAMPUSINSULIN GROWTH FACTOR 1MICROGLIAL CELLSNEURODEGENERATIONNEUROGENESISNEUROINFLAMMATIONSPINAL CORD INJURYTRAUMATIC BRAIN INJURYhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Although little attention has been paid to cognitive and emotional dysfunctions observed in patients after spinal cord injury, several reports have described impairments in cognitive abilities. Our group also has contributed significantly to the study of cognitive impairments in a rat model of spinal cord injury. These findings are very significant because they demonstrate that cognitive and mood deficits are not induced by lifestyle changes, drugs of abuse, and combined medication. They are related to changes in brain structures involved in cognition and emotion, such as the hippocampus. Chronic spinal cord injury decreases neurogenesis, enhances glial reactivity leading to hippocampal neuroinflammation, and triggers cognitive deficits. These brain distal abnormalities are recently called tertiary damage. Given that there is no treatment for Tertiary Damage, insulin growth factor 1 gene therapy emerges as a good candidate. Insulin growth factor 1 gene therapy recovers neurogenesis and induces the polarization from pro-inflammatory towards anti-inflammatory microglial phenotypes, which represents a potential strategy to treat the neuroinflammation that supports tertiary damage. Insulin growth factor 1 gene therapy can be extended to other central nervous system pathologies such as traumatic brain injury where the neuroinflammatory component is crucial. Insulin growth factor 1 gene therapy could emerge as a new therapeutic strategy for treating traumatic brain injury and spinal cord injury.Fil: Bellini, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner". Universidad Nacional de la Plata. Facultad de Ciencias Médicas. Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner"; ArgentinaFil: Labombarda, Maria Florencia. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaShenyang Editorial Dept Neural Regeneration Res2023-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/227270Bellini, Maria Jose; Labombarda, Maria Florencia; Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy; Shenyang Editorial Dept Neural Regeneration Res; Neural Regeneration Research; 18; 2; 2-2023; 253-2571673-5374CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.4103/1673-5374.343902info:eu-repo/semantics/altIdentifier/url/https://journals.lww.com/nrronline/fulltext/2023/02000/brain_and_spinal_cord_trauma__what_we_know_about.3.aspxinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:46:16Zoai:ri.conicet.gov.ar:11336/227270instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:46:16.561CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy
title Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy
spellingShingle Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy
Bellini, Maria Jose
COGNITIVE IMPAIRMENTS
GENE THERAPY
HIPPOCAMPUS
INSULIN GROWTH FACTOR 1
MICROGLIAL CELLS
NEURODEGENERATION
NEUROGENESIS
NEUROINFLAMMATION
SPINAL CORD INJURY
TRAUMATIC BRAIN INJURY
title_short Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy
title_full Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy
title_fullStr Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy
title_full_unstemmed Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy
title_sort Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy
dc.creator.none.fl_str_mv Bellini, Maria Jose
Labombarda, Maria Florencia
author Bellini, Maria Jose
author_facet Bellini, Maria Jose
Labombarda, Maria Florencia
author_role author
author2 Labombarda, Maria Florencia
author2_role author
dc.subject.none.fl_str_mv COGNITIVE IMPAIRMENTS
GENE THERAPY
HIPPOCAMPUS
INSULIN GROWTH FACTOR 1
MICROGLIAL CELLS
NEURODEGENERATION
NEUROGENESIS
NEUROINFLAMMATION
SPINAL CORD INJURY
TRAUMATIC BRAIN INJURY
topic COGNITIVE IMPAIRMENTS
GENE THERAPY
HIPPOCAMPUS
INSULIN GROWTH FACTOR 1
MICROGLIAL CELLS
NEURODEGENERATION
NEUROGENESIS
NEUROINFLAMMATION
SPINAL CORD INJURY
TRAUMATIC BRAIN INJURY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Although little attention has been paid to cognitive and emotional dysfunctions observed in patients after spinal cord injury, several reports have described impairments in cognitive abilities. Our group also has contributed significantly to the study of cognitive impairments in a rat model of spinal cord injury. These findings are very significant because they demonstrate that cognitive and mood deficits are not induced by lifestyle changes, drugs of abuse, and combined medication. They are related to changes in brain structures involved in cognition and emotion, such as the hippocampus. Chronic spinal cord injury decreases neurogenesis, enhances glial reactivity leading to hippocampal neuroinflammation, and triggers cognitive deficits. These brain distal abnormalities are recently called tertiary damage. Given that there is no treatment for Tertiary Damage, insulin growth factor 1 gene therapy emerges as a good candidate. Insulin growth factor 1 gene therapy recovers neurogenesis and induces the polarization from pro-inflammatory towards anti-inflammatory microglial phenotypes, which represents a potential strategy to treat the neuroinflammation that supports tertiary damage. Insulin growth factor 1 gene therapy can be extended to other central nervous system pathologies such as traumatic brain injury where the neuroinflammatory component is crucial. Insulin growth factor 1 gene therapy could emerge as a new therapeutic strategy for treating traumatic brain injury and spinal cord injury.
Fil: Bellini, Maria Jose. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner". Universidad Nacional de la Plata. Facultad de Ciencias Médicas. Instituto de Investigaciones Bioquímicas de La Plata "Prof. Dr. Rodolfo R. Brenner"; Argentina
Fil: Labombarda, Maria Florencia. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
description Although little attention has been paid to cognitive and emotional dysfunctions observed in patients after spinal cord injury, several reports have described impairments in cognitive abilities. Our group also has contributed significantly to the study of cognitive impairments in a rat model of spinal cord injury. These findings are very significant because they demonstrate that cognitive and mood deficits are not induced by lifestyle changes, drugs of abuse, and combined medication. They are related to changes in brain structures involved in cognition and emotion, such as the hippocampus. Chronic spinal cord injury decreases neurogenesis, enhances glial reactivity leading to hippocampal neuroinflammation, and triggers cognitive deficits. These brain distal abnormalities are recently called tertiary damage. Given that there is no treatment for Tertiary Damage, insulin growth factor 1 gene therapy emerges as a good candidate. Insulin growth factor 1 gene therapy recovers neurogenesis and induces the polarization from pro-inflammatory towards anti-inflammatory microglial phenotypes, which represents a potential strategy to treat the neuroinflammation that supports tertiary damage. Insulin growth factor 1 gene therapy can be extended to other central nervous system pathologies such as traumatic brain injury where the neuroinflammatory component is crucial. Insulin growth factor 1 gene therapy could emerge as a new therapeutic strategy for treating traumatic brain injury and spinal cord injury.
publishDate 2023
dc.date.none.fl_str_mv 2023-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/227270
Bellini, Maria Jose; Labombarda, Maria Florencia; Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy; Shenyang Editorial Dept Neural Regeneration Res; Neural Regeneration Research; 18; 2; 2-2023; 253-257
1673-5374
CONICET Digital
CONICET
url http://hdl.handle.net/11336/227270
identifier_str_mv Bellini, Maria Jose; Labombarda, Maria Florencia; Brain and spinal cord trauma: What we know about the therapeutic potential of insulin growth factor 1 gene therapy; Shenyang Editorial Dept Neural Regeneration Res; Neural Regeneration Research; 18; 2; 2-2023; 253-257
1673-5374
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.4103/1673-5374.343902
info:eu-repo/semantics/altIdentifier/url/https://journals.lww.com/nrronline/fulltext/2023/02000/brain_and_spinal_cord_trauma__what_we_know_about.3.aspx
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Shenyang Editorial Dept Neural Regeneration Res
publisher.none.fl_str_mv Shenyang Editorial Dept Neural Regeneration Res
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268782301544448
score 13.13397

Publicaciones similares